Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | IGFBP5 | P24593 | 6/20 | 0.43 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079837 | 0.89 | P2RX3 (0.42) | HCAR2IGFBP5IGFBP3KDM4EKMT2A | |
| SCHEMBL6080822 | 0.85 | RNASEH1 (0.44) | IDH1MPOKDM4EMAPT | |
| SCHEMBL6080032 | 0.85 | KDM4E (0.41) | HCAR2IGFBP5IGFBP3KDM4E | |
| SCHEMBL6594866 | 0.83 | PTGER1 (0.44) | HCAR2MAPTRAB9A | |
| SCHEMBL21987014 | 0.81 | HNF4A (0.53) | HCAR2HNF4AIGFBP5IGFBP3IDH1 | |
| SCHEMBL6080363 | 0.78 | HCAR2 (0.42) | HCAR2IGFBP5IGFBP3PTPN1KDM4E | |
| SCHEMBL6080080 | 0.78 | MCL1 (0.46) | HNF4APTPN1ACMSDKDM4EKMT2A | |
| SCHEMBL6080526 | 0.77 | IGFBP5 (0.37) | IGFBP5IGFBP3KDM4EKMT2AMAPT | |
| SCHEMBL6080777 | 0.77 | P2RX3 (0.39) | HCAR2IGFBP5IGFBP3KDM4EKMT2A | |
| SCHEMBL6080530 | 0.76 | IGFBP5 (0.36) | IGFBP5IGFBP3KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | HCAR2 3606/4885HNF4A 1848/4885IGFBP5 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.